Chris Gallagher

Chris Gallagher

Chris Gallagher is President of IP Strategic.com and a perennial selection to The Best Lawyers in America. Having spent years as one of the most influential and highly regarded advocates in the New Hampshire Legislature and state administrative agencies, Chris is now focused primarily on federal policies in Washington, DC. Chris has been involved in nearly every substantial New Hampshire economic regulatory initiative over the last 25 years. He has served as general counsel for the New Hampshire Bankers Association and has represented New Hampshire utilities, hospitals, insurers, aggregate manufacturers and numerous other entities. This experience provides him with a uniquely respected voice on Capitol Hill, enabling him to communicate effectively with members whose federal decision-making must reflect and respect the complexities of their home-state constituents.

A frequent speaker and commentator in local and national media on policy issues, regarding financial services, privacy, business and government, Chris has testified on financial services issues before U.S. House and Senate Committees and has been a panelist in Capitol Hill briefings on intellectual property issues. He can be reached at chris@ipstrategic.com


Posts by Chris Gallagher


Confused and frustrated, patent policy experts bemoan America’s absurd compulsory licensing patent system

The experts in attendance reminded us of the insanity of the compulsory licensing system that now pervades the U.S. patent marketplace, which when explained in terms …
By Chris Gallagher
2 months ago 23

Patent troll narrative returns to Capitol Hill as relentless push for patent reform continues

The beauty of the patent troll narrative was it took little time to absorb and instantly painted a pejorative picture in the minds-eye of the listener. It …
By Chris Gallagher & Gene Quinn
3 months ago 9

Studying IPRs Not Enough, PTAB must be Repaired, Replaced or Repealed by Congress

Inter Partes Review (IPR) is viewed by many as late-stage destruction of fully developed early-stage investor ROI in patented property. The Lee study will presumably weigh the …
By Chris Gallagher
3 months ago 23

Early Stage Innovation’s Chance to Save Itself

Universities in particular must explain to their congressional delegations why R&D must continue to be funded and why its Bayh-Dole based commercialization bridge must be protected …
By Chris Gallagher
5 months ago 0

Will President Trump directly negotiate Medicare prescription drug pricing?

The savings impact of directly negotiated drug costs is considered negligible, but intrusion into biomedical pricing will destabilize life science commercialization... Any way you slice it, added …
By Chris Gallagher
5 months ago 2

Commercialization of University Research Threatened by Proposed State Legislation 

EFF’s Reclaim Invention Act, Draft Model Statute may seem an odd approach to folks in DC but when lined up with a state-level lobby of IP-uninformed …
By Chris Gallagher
8 months ago 4

Canada’s Promise Doctrine Should Be a Warning to America

A recent Canadian survey (CRA Survey) has conclusively attributed lowered levels of R&D investment in Canada’s innovation ecosystem to the country’s unique judicial “Promise …
By Chris Gallagher
9 months ago 11

Move over Patent Trolls, Efficient Infringement has arrived on the Hill

But now, after quickly dispatching with the patent troll meme as much ado about nothing, we can, should and must now unleash a more simplified counter attack …
By Chris Gallagher & Gene Quinn
9 months ago 18

The UN has Better Things to do Than Destroy Innovation

The UN Panel unfortunately squandered its 9-month gestation period. It stuffed into one repository every long-discarded remnant of anti-patent and pro-price-control schemes buried in IP’s historic …
By Chris Gallagher
10 months ago 2

The EpiPen Episode’s Silver Lining

EpiPen's eruptive timing was important. Had Congress been in town, lawmakers would have filled the front pages with populist blather. Had Mylan been less forthcoming about the …
By Chris Gallagher
11 months ago 11

Research Universities Face Licensing Limitations Sought by Electronic Frontier Foundation

Another incursion into research university governance and operations is now underway. And this time all research universities are affected. Led by the DC Based Electronic Frontier Foundation, …
By Chris Gallagher
11 months ago 3

Public Health and Bioscientific War on Superbugs is Hobbled by IP Uncertainties

How will our patent system treat this wonderful new discovery? How long will it take before its curative benefits can be deployed ? We can only hope that …
By Chris Gallagher
12 months ago 5

The superbugs are here, but where are we?

Superbugs have powerful friends in high places. SCOTUS’s patent eligibility criteria emanating from Mayo/Alice’s mysterious “laws of nature” and credible reports of unremitting turndowns …
By Chris Gallagher
1 year ago 6

UN Access to Medicines Panel Undermines Bayh-Dole 

We cannot know what biological killer will next emerge, when it will be born and where globalization’s winds will take it. But we do know that …
By Chris Gallagher
1 year ago 1

A Good Opportunity to Reframe the Patent Reform Debate

Corrosive changes in patent law are undermining research university commercialization of patented, federally-funded basic research, endangering our nation’s innovation ecosystem. Mounting uncertainty repels private investment needed …
By Chris Gallagher
1 year ago 9